NECTIN4 and urothelial carcinoma: Recent phase I and II trials demonstrated the efficacy of enfortumab vedotin (EV), which targets Nectin-4 in urothelial carcinoma patients who exhibit tumor progression after platinum chemotherapy and/or immune checkpoint inhibitors [4,5].